Table 3.
Group | Mean rank | Kruskal–Wallis H | P value |
---|---|---|---|
EXplb (n = 12) | 10.2 | 19.704 | < 0.001 |
EXdtz (n = 11) | 18.8 | ||
NEplb (n = 8) | 25.4 | ||
NEdtz (n = 9) | 32.0 |
Pairwise comparison | Mean rank difference | Standard error | P valuea |
---|---|---|---|
EXplb–NEdtz | − 21.83 | 5.16 | < 0.001 |
EXplb–NEplb | − 15.21 | 5.34 | 0.026 |
EXplb–EXdtz | − 8.65 | 4.88 | 0.457 |
EXdtz–NEdtz | − 13.18 | 5.25 | 0.073 |
EXdtz–NEplb | − 6.56 | 5.43 | 1.000 |
NEdtz–NEplb | − 6.62 | 5.68 | 1.000 |
EXplb CYP3A5 expressers with placebo group, EXdtz CYP3A5 expressers with diltiazem group, NEplb CYP3A5 nonexpressers with placebo group, NEdtz CYP3A5 nonexpressers with diltiazem group.
aBonferroni correction for multiple comparisons.